212.40 How must I control the components I use to produce PET drugs and the containers and closures I package them in?

212.50 What production and process controls must I have?

212.60 What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products?

212.61 What must I do to ensure the stability of my PET drug products through expiry?

212.70 What controls and acceptance criteria must I have for my finished PET drug products?

212.71 What actions must I take if a batch of PET drug product does not conform to specifications?

212.80 What are the requirements associated with labeling and packaging PET drug products?

212.90 What actions must I take to control the distribution of PET drug products?

212.100 What do I do if I receive a complaint about a PET drug product produced at my facility?

212.110 How must I maintain records of my production of PET drugs?

212.1 What are the meanings of the technical terms used in these regulations?

The following definitions apply to words and phrases as they are used in this part. Other definitions of these words may apply when they are used in other parts of this chapter.

**Acceptance criteria** means numerical limits, ranges, or other criteria for tests that are used for or in making a decision to accept or reject a unit, lot, or batch of a PET drug product.

**Act** means the Federal Food, Drug, and Cosmetic Act, as amended (21 U.S.C. 321 et seq.).

**Active pharmaceutical ingredient** means a substance that is intended for incorporation into a finished PET drug product and is intended to furnish pharmacological activity or other direct effect in the diagnosis or monitoring of a disease or a manifestation of a disease in humans, but does not include intermediates used in the synthesis of such substance.

**Batch** means a specific quantity of PET drug intended to have uniform character and quality, within specified limits, that is produced according to a single production order during the same cycle of production.

**Batch production and control record** means a unique record that references an accepted master production and control record and documents specific details on production, labeling, and quality control for a single batch of a PET drug.

**Component** means any ingredient intended for use in the production of a PET drug, including any ingredients that may not appear in the final PET drug product.

**Conditional final release** means a final release made prior to completion of a required finished-product test because of a malfunction involving analytical equipment.

**Final release** means the authoritative decision by a responsible person in a PET production facility to permit the use of a batch of a PET drug in humans.

**Inactive ingredient** means any intended component of the PET drug other than the active pharmaceutical ingredient.

**In-process material** means any material fabricated, compounded, blended, or derived by chemical reaction that is produced for, and is used in, the preparation of a PET drug.
§ 212.2 What is current good manufacturing practice for PET drugs?

Current good manufacturing practice for PET drugs is the minimum requirements for the methods to be used in, and the facilities and controls used for, the production, quality assurance, holding, or distribution of PET drugs intended for human use. Current good manufacturing practice is intended to ensure that each PET drug meets the requirements of the act as to safety.